Search: (WFRF:(Radford John)) conttype:(scientificother) >
A Randomized Study ...
A Randomized Study of Interferon alpha-2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma
- Article/chapterEnglish2013
Publisher, publication year, extent ...
-
2013-10-08
-
Oxford University Press (OUP),2013
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-214322
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-214322URI
-
https://doi.org/10.1634/theoncologist.2013-0223DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:vet swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background. Patients with lymphoma who have experienced a first relapse or progression and have disease deemed sensitive to salvage chemotherapy nevertheless have a high likelihood of having a second relapse. To decrease the likelihood of a second relapse after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT), interferon (IFN) alpha-2b was given in a prospective randomized international trial. Methods. In this trial, 221 patients with varying histologic diagnoses (8 small lymphocytic, 37 follicular, 9 mantle, 90 diffuse large B-cell, 20 peripheral T-cell, 3 high-grade B-cell non-Hodgkin lymphoma, and 54 Hodgkin lymphoma) were randomly assigned to receive no further treatment (armA: 117 patients) or IFN alpha-2b, 3 MU three times weekly, for 18 months (arm B: 104 patients). Results. In arm B, 21 patients (20%) did not receive IFN alpha-2b because of early progression or absence of hematologic recovery, 29 patients (28%) completed the 18 months of treatment, and 54 patients (52%) interrupted treatment because of progression (23%) or toxicity (29%). Event-free survival and overall survival were not different between the two arms on an intent-to-treat analysis and also if analysis was restricted to patients who were a live and had not experienced disease progression three months after transplantation. The study was not sufficiently powered to evaluate effects in histologic subtypes. Conclusion. In this trial, post-autograft IFN alpha-2b did not improve outcomes in a heterogeneous group of patients with lymphoma.
Added entries (persons, corporate bodies, meetings, titles ...)
-
Grigg, Andrew
(author)
-
Holte, Harald
(author)
-
Gisselbrecht, Christian
(author)
-
Radford, John
(author)
-
Rossi, Andrea
(author)
-
Lopez-Guillermo, Armando
(author)
-
Trneny, Marek
(author)
-
Sebban, Catherine
(author)
-
Hagberg, HansUppsala universitet,Enheten för onkologi(Swepub:uu)hanshagb
(author)
-
da Costa, Fernando Leal
(author)
-
Colombat, Philippe
(author)
-
Bron, Dominique
(author)
-
Coiffier, Bertrand
(author)
-
Uppsala universitetEnheten för onkologi
(creator_code:org_t)
Related titles
-
In:The Oncologist: Oxford University Press (OUP)18:11, s. 1189-11891083-71591549-490X
Internet link
Find in a library
To the university's database
- By the author/editor
-
Bosly, Andre
-
Grigg, Andrew
-
Holte, Harald
-
Gisselbrecht, Ch ...
-
Radford, John
-
Rossi, Andrea
-
show more...
-
Lopez-Guillermo, ...
-
Trneny, Marek
-
Sebban, Catherin ...
-
Hagberg, Hans
-
da Costa, Fernan ...
-
Colombat, Philip ...
-
Bron, Dominique
-
Coiffier, Bertra ...
-
show less...
- Articles in the publication
-
The Oncologist
- By the university
-
Uppsala University